EUROPE AND MEA CULTURE TEST FOR HEALTHCARE ASSOCIATED INFECTIONS MARKET Size and trends

Europe And Mea Culture Test For Healthcare Associated Infections Market Size and Trends

The Europe and MEA Culture Test for Healthcare-associated Infections Market is estimated to be valued at USD 299.1 Mn in 2025 and is expected to reach USD 370.3 Mn by 2032, exhibiting a compound annual growth rate (CAGR) of 3.1% from 2025 to 2032.

Key Takeaways of the Europe and MEA Culture Test for Healthcare-associated Infections Market:

• In terms of product type, the instruments segment is estimated to account for the highest share of 52.2% of the Europe and MEA culture test for healthcare-associated infections market in 2025
• In terms of test type, the bacterial culture tests segment is estimated to hold the highest market share of 34% of the Europe and MEA culture test for healthcare-associated infections market in 2025.
• In terms of application, the surgical site infections segment is estimated to hold the highest market share of 27% of the market in 2025.

Market Overview:

The Europe and MEA culture test for healthcare-associated infections market is expected to witness moderate growth over the forecast period. The growing prevalence of hospital-acquired infections, such as pneumonia, urinary tract infections, and bloodstream infections, is expected to drive the demand for culture tests for early diagnosis and management. Additionally, increasing healthcare expenditure and rising awareness about the early detection of infections are further expected to support the market growth during the forecast period. However, the availability of alternative diagnostic tests and lack of skilled professionals may hamper the market growth to some extent.

To learn more about this report, Request sample copy

Key Developments:

• In July 2024, Midmark Corporation, a leading provider of medical equipment solutions, launched its next-generation M11 and M9 steam sterilizers, designed for enhanced durability, ease of use, and improved compliance documentation and instrument processing efficiencies
• In July 2023, Merck, a global leader in life sciences, expanded its Kansas, U.S. facility, now the largest dry powder cell culture media facility and Center of Excellence in North America. The 9,100 sq. meter expansion boosts production capacity to meet growing global demand for cell culture media, critical for biomanufacturing and life-saving therapies.
• In June 2023, MMM Group, a global sterilization specialist, partnered with Southwest Clinic to establish a state-of-the-art CSSD/RUMED facility at Kreiskliniken Calw clinic in Germany. This advanced facility reprocesses critical medical products for four clinics, ensuring high standards in medical care.

Top Strategies Followed by Europe and MEA Culture Test for Healthcare-associated Infections Market Players

• Established Players: Leading companies in Europe and MEA culture test for healthcare-associated infections market, such as Abbott Laboratories and Merck KGaA, focus heavily on research and development to innovate high-performance products.
  • For instance, in February 2024, Abbott's recent investment in developing rapid diagnostic tests has significantly enhanced its product offerings, allowing for quicker identification of pathogens associated with healthcare-associated infections (HAIs).
• Mid-Level Players: Mid-level companies are focusing on delivering quality, budget-friendly products targeting price-sensitive consumers. Companies like Thermo Fisher Scientific have introduced cost-effective cell culture media that maintain high standards while being accessible to smaller laboratories.
  • Small-Scale Players: Small players often target niche markets with unique features or innovative products. For example, SSI Diagnostica A/S specializes in specific culture tests for antibiotic-resistant bacteria, catering to a growing demand for specialized diagnostics. The use of cutting-edge technologies, such as automated culture systems, allows small-scale players to remain competitive. Companies like Hardy Diagnostics are leveraging automation to streamline its testing processes, enhancing efficiency and accuracy.

Emerging Startups - Europe and MEA Culture Test for Healthcare-associated Infections Industry Ecosystem

• Innovative Technologies: Startups like QIAGEN N.V. are developing advanced technologies, including smart sensors and AI-driven diagnostic tools, which have the potential to revolutionize the culture testing landscape. These innovations can significantly improve the speed and accuracy of infection detection, impacting market dynamics positively.
• Sustainable Solutions: While specific examples in the Europe and MEA culture test for healthcare-associated infections market are limited, the broader healthcare industry in Europe and MEA is seeing startups focusing on sustainability, such as developing eco-friendly diagnostic kits and utilizing recycled materials in manufacturing.
• Market Contribution: Emerging startups are addressing unique market needs by developing specialized diagnostic tools tailored for specific healthcare-associated infections, thereby filling gaps left by larger players. Partnerships with established companies or research institutions are common among startups. These collaborations drive technological innovation and facilitate the development of advanced culture tests for HAIs.